Clinical Trials on Pigmented Nevi

Total 2851 results

Karolinska University Hospital

Recruiting

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Melanoma

Sweden
Vanderbilt-Ingram Cancer Center

Recruiting

Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment

Melanoma

United States
Craig L Slingluff, Jr
Celldex Therapeutics

Completed

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65)

Melanoma

United States
Highlight Therapeutics
Merck Sharp & Dohme LLC

Active, not recruiting

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203)

Melanoma

Spain, France
Dana-Farber Cancer Institute

Active, not recruiting

Dendritic Cell Activating Scaffold in Melanoma

Melanoma

United States
University of Utah

Completed

Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy

Melanoma
John O. Prior

Terminated

Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma (Tilmanocept)

Melanoma

Switzerland
Zarour, Hassane, MD
Merck Sharp & Dohme LLC

Active, not recruiting

Fecal Microbiota Transplant (FMT) in Melanoma Patients

Melanoma

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

Melanoma

United States
Memorial Sloan Kettering Cancer Center
University of British Columbia; San Diego State University; Stony Brook University

Active, not recruiting

Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection

Melanoma

United States
Institut Claudius Regaud

Active, not recruiting

Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients (IMMUSPHINX)

Melanoma

France
Hoffmann-La Roche

Completed

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Melanoma

China
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Melanoma

Canada, Australia, France, Italy, Brazil, United States, Argentina, Austria, Belgium, Chile, Czechia, Finland, Germany, Greece, Ireland, Israel, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain, Sweden and more
Massachusetts General Hospital
Incyte Corporation

Terminated

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Melanoma

United States
University of Colorado, Denver

Completed

Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

Melanoma

United States
Haukeland University Hospital
BerGenBio ASA

Active, not recruiting

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Melanoma

Norway
University of California, Davis
Amgen

Suspended

Neoadjuvant T-VEC in High Risk Early Melanoma

Melanoma

United States
Novartis Pharmaceuticals

Completed

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD)

Melanoma

United States, Belgium, Canada, Spain, United Kingdom, Netherlands, Argentina, Australia, Austria, Brazil, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, New Zealand, Norway, Poland, Russian Federation, Sweden, Switz... and more
Memorial Sloan Kettering Cancer Center
Schering-Plough

Completed

Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma

Melanoma

United States
BioNTech SE

Completed

Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma (Lipo-MERIT)

Melanoma

Germany
Memorial Sloan Kettering Cancer Center
Array BioPharma

Completed

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Melanoma

United States
QBiotics Group Limited

Terminated

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

Melanoma

Australia
QBiotics Group Limited
Merck Sharp & Dohme LLC

Terminated

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Melanoma

Australia
Melanoma and Skin Cancer Trials Limited
Trans Tasman Radiation Oncology Group

Active, not recruiting

Neurotropic Melanoma of the Head and Neck (RTN2)

Melanoma

United States, Australia, United Kingdom
Memorial Sloan Kettering Cancer Center
Rockefeller University

Completed

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

Melanoma

United States
University Hospital, Ghent
GZA Ziekenhuizen Campus Sint-Augustinus

Completed

A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.

Melanoma

Belgium
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb

Completed

Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

Melanoma

United States
Centre Antoine Lacassagne

Terminated

Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas (HYGROMEL)

Melanoma

France
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)

Melanoma
Amgen
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma (MASTERKEY-265)

Melanoma

United States, Finland, France, Germany, Italy, Canada, Czechia, Poland, Switzerland, Korea, Republic of, Russian Federation, United Kingdom, Australia, Netherlands, Spain, Austria, Belgium, Hungary, Portugal, Greece, South Africa
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Tracing Dissemination of Melanoma Cells in Healthy Tissues (DISSEMELA)

Melanoma

France
NewLink Genetics Corporation

Terminated

A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma (NLG2107)

Melanoma

United States
Zuyderland Medisch Centrum

Completed

Sentinel Lymph Node Mapping Using Magtrace and MRI in Healthy Subjects for Potential Use in Melanoma Patients (TRACIE)

Melanoma

Netherlands
Bristol-Myers Squibb

Completed

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066)

Melanoma

Canada, Australia, Germany, Italy, Poland, France, Denmark, Argentina, Chile, Spain, Norway, Israel, Sweden, Mexico, Greece, Finland
University of Wisconsin, Madison
National Cancer Institute (NCI)

Completed

Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma

Melanoma

United States
Bristol-Myers Squibb

Completed

A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

Melanoma

Australia
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Study of PI-88 in Patients With Advanced Melanoma

Melanoma

United States
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
Bristol-Myers Squibb

Completed

Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study

Melanoma

United States
Gary Doolittle

Completed

Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma (MARVSmALo)

Melanoma

United States
Yana Najjar
Merck Sharp & Dohme LLC

Terminated

Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma

Melanoma

United States
Institut Claudius Regaud

Completed

TNF in Melanoma Patients Treated With Immunotherapy (MELANFα)

Melanoma

France
Massachusetts General Hospital

Active, not recruiting

Utility of Novel BRAF Test for Melanoma

Melanoma

United States
Nantes University Hospital
Bristol-Myers Squibb

Completed

Post-ATU Study of Nivolumab (Post-ATU)

Melanoma

France
Bristol-Myers Squibb

Withdrawn

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants (CheckMate 7UA)

Melanoma

France, Italy, Poland, United States, Brazil, Spain, Australia, Denmark, Germany, Austria, Netherlands, Russian Federation, Belgium, United Kingdom, Sweden, Switzerland
Northwestern University

Completed

Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners (PSW)

Melanoma

United States
Novartis Pharmaceuticals

Completed

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma (COMBI-v)

Melanoma

United States, United Kingdom, Austria, Belgium, Hungary, Canada, Netherlands, Argentina, Australia, Brazil, Czechia, Denmark, France, Germany, Israel, Italy, Norway, Poland, Russian Federation, Spain, Switzerland, Taiwan, Korea, Republic... and more
Taizhou HoudeAoke Biomedical Co., Ltd.

Unknown

A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma

Melanoma

China
Peking University Cancer Hospital & Institute

Active, not recruiting

Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma

Melanoma

China
University of Chicago
Eisai Inc.

Terminated

Vaccination Plus Ontak in Patients With Metastatic Melanoma

Melanoma

United States

Clinical Trials on Pigmented Nevi

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations